Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least. Meanwhile, secondary outcomes will include changes in some biomarkers and on specifically local brain activity (functional Magnetic Resonance Imaging, fMRI) and white matter integrity (Diffusion Tensor Imaging, DTI). The hypothesis of this study is that NAC has positive effects on refractory major depressive disorder patients with increased inflammatory activity.


Clinical Trial Description

It's a double-blind randomised placebo controlled antidepressant augmentation study with 12-week treatment and 8-week follow up. Its purpose is to investigate antidepressant efficacy and safety of NAC in patients with treatment resistant depression (TRD) defined as insufficient response to 1 or more antidepressants given for at least 6 weeks and in an adequate dose, displaying increased peripheral inflammatory activity and moderate to severe depression. Apart from studying the effects of NAC on depression severity, the secondary outcomes are to examine a range of biomarkers related to potentially important underlying mechanisms such as oxidative stress and inflammatory activity and to evaluate the effects on brain functioning (fMRI) and on white matter integrity (DTI). Scale assessments are performed in the week preceding initiation of treatment, during the treatment period, at the end of the treatment period and at 8-week follow up. Neuro-imaging is performed before the treatment starts and in week 12, before the study medication is terminated. Collection of blood and morning urine only takes place at three time points, in the week preceding initiation of treatment, closely before tapering off the study medication and at the end of 8-week follow up. This study is hoped to show that NAC perform positive effects on those aspects mentioned above. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02972398
Study type Interventional
Source Tianjin Anding Hospital
Contact Chenghao Yang, Master
Phone 086 13752539531
Email yts83420@163.com
Status Recruiting
Phase N/A
Start date September 2015
Completion date September 2023

See also
  Status Clinical Trial Phase
Completed NCT00855530 - Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder Phase 3
Completed NCT00825019 - Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine Phase 3
Completed NCT02829671 - Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas N/A
Recruiting NCT02681822 - Multi-center Imaging Genetics Studies in China
Completed NCT00825058 - Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine Phase 3
Recruiting NCT04497493 - Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder N/A
Completed NCT01347138 - Health Care Management for the Elderly in Community Through Screening N/A
Completed NCT01377896 - The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours N/A
Completed NCT02449447 - Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet N/A
Completed NCT06239740 - Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder N/A
Not yet recruiting NCT02942251 - Relapse Predicting Model for First Episode Depression N/A
Recruiting NCT02590185 - MetAbolism vaRiability of VEnLafaxine N/A